Grifols, a global healthcare company and manufacturer of plasma-derived medicines, has entered a collaboration agreement with Google Cloud to leverage technologies such as artificial intelligence (AI) to help accelerate the development of new biopharma medicines.
 
AI featuring large language models will be applied across the drug-development life cycle, including identifying potential therapeutic candidates and managing clinical trial programs, with the goal of significantly reducing the time required to bring new treatments to market.
 
The result will be a new Grifols scientific information platform with deep Grifols-owned internal and external data sets that can be rapidly mined for insights on diseases and pharmacology. Discovering disease-identifying biomarkers at an early stage can lead to more effective treatments and can also surface trends among specific cohorts, yielding more personalized medicine.
 
Grifols will explore new applications and use cases for data and AI in the biopharma sector. It will also work with Google Cloud on sharing best practices in innovation including new technologies, prototype quick testing and rapid scaling. 
 
“Grifols will reinvent biopharma medicine as we know it so we can bring more treatments to more patients in more parts of the world,” said Albert Grifols Coma-Cros, Grifols Chief Scientific Innovation Officer. “Turbocharging our extensive knowledge of biopharma and plasma science with the most advanced data technologies from Google Cloud will benefit patients and society.”
 
“We are thrilled to partner with Grifols to help the company accelerate its R&D efforts and improve patient care,” said Isaac Hernández, GM of Google Cloud Iberia. “Our data and generative AI capabilities can help Grifols glean new insights, accelerate the discovery of new drugs and therapies, and improve the efficiency of its manufacturing processes.”